Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/B978-0-444-52902-2.00001-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation Induced Unilateral Vocal Fold Paralysis Following Lung Stereotactic Ablative Radiation Therapy: A Case Report and Review of the Literature.
Clin Lung Cancer
December 2024
Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:
Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
View Article and Find Full Text PDFMorphine treatment restricts response to immunotherapy in oral squamous cell carcinoma.
J Immunother Cancer
November 2024
Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Background: Immune checkpoint inhibitors (ICIs) are becoming the standard of care for recurrent and metastatic cancer. Opioids, the primary treatment for cancer-related pain, are immunosuppressive raising concerns about their potential to interfere with the efficacy of ICIs. We hypothesize that exogenous opioids given for analgesia suppress antitumor immunity via T cell-mediated mu opioid receptor 1 (OPRM1) signaling.
View Article and Find Full Text PDFRadiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Lancet Oncol
December 2024
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Background: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy with cetuximab.
Methods: NRG-HN004 was designed as an open-label, multicentre, parallel-group, randomised, phase 2/3 trial with safety lead-in conducted at 89 academic and community medical centres in North America.
Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.
Radiother Oncol
January 2025
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:
Article Synopsis
- This study investigates the progression patterns and outcomes of anaplastic thyroid cancer (ATC) patients with neck disease who received high-dose intensity-modulated radiation therapy (IMRT), focusing on those with unresected or partially resected tumors. !* -
- The analysis included 40 patients treated from 2010 to 2020, revealing a median overall survival of 7.1 months and a median progression-free survival of 7.4 months for those with locoregional disease. !* -
- The findings indicate that despite aggressive treatment, 53% of patients experienced loco-regional progression, predominantly in highly irradiated areas, emphasizing the need for improved targeting and strategy in treatment planning. !
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!